Debt-free Balance SheetThe company’s debt-free balance sheet and substantial equity materially reduce financial risk and provide strategic flexibility. Over the next 2–6 months this supports funding for R&D, product development or working-capital needs without reliance on external debt, stabilizing operations while profits recover.

Return To Positive Cash Flow (2025)Positive operating and free cash flow in 2025 signals improved cash discipline and lowers near-term funding risk. If sustained, this enables self-funding of operations and targeted investments, reduces dilution risk, and improves resilience through typical biotech funding cycles and development timelines.

High Gross MarginsStable gross margins near 50% provide structural profit potential if revenue stabilizes. High gross margins indicate pricing power or efficient production, allowing operating leverage to drive margin recovery faster as sales recover or fixed costs are optimized, supporting longer-term profitability.

Bears Say

Deteriorated ProfitabilitySwinging to net losses in 2024–2025 shows profitability has deteriorated materially. Persistent negative margins erode equity, constrain reinvestment and hiring, and raise the bar for recovery; management must restore sustainable operating profit to avoid recurring funding or strategic compromises.

Declining Revenue TrendMulti-year revenue decline (negative growth in 2023–2025) signals weakening demand or execution issues. Prolonged top-line shrinkage undermines scale economies, reduces headroom for fixed-cost absorption, and makes margin recovery and durable profitability harder without product, commercial or market inflection.

Volatile Cash GenerationCash generation has been uneven, creating unpredictability in funding operations and investments. This volatility increases execution risk, complicates multi-year planning and capital allocation, and could force dilutive financing or project delays if the positive 2025 cash outcome does not persist.

2385 FAQ

What was Soiken Holdings Inc.’s price range in the past 12 months?

Soiken Holdings Inc. lowest stock price was ¥116.00 and its highest was ¥325.00 in the past 12 months.

What is Soiken Holdings Inc.’s market cap?

Soiken Holdings Inc.’s market cap is ¥6.62B.

When is Soiken Holdings Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Soiken Holdings Inc.’s earnings last quarter?

Currently, no data Available

Is Soiken Holdings Inc. overvalued?

According to Wall Street analysts Soiken Holdings Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Soiken Holdings Inc. pay dividends?

Soiken Holdings Inc. pays a Annually dividend of ¥5 which represents an annual dividend yield of 2.08%. See more information on Soiken Holdings Inc. dividends here

What is Soiken Holdings Inc.’s EPS estimate?

Soiken Holdings Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Soiken Holdings Inc. have?

Soiken Holdings Inc. has 26,158,200 shares outstanding.

What happened to Soiken Holdings Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Soiken Holdings Inc.?

Currently, no hedge funds are holding shares in JP:2385

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Soiken Holdings Inc.

Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for physician-led pharmaceutical clinical research, health checkups, and specific health guidance; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.